Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA:600332)
22.87
-0.09 (-0.39%)
Apr 29, 2026, 3:00 PM CST
SHA:600332 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 2,946 | 2,983 | 2,835 | 4,056 | 3,967 | 3,720 | Upgrade
|
| Depreciation & Amortization | 865.94 | 865.94 | 875.24 | 929.44 | 743.83 | 676.99 | Upgrade
|
| Other Amortization | 89.91 | 89.91 | 60.96 | 55.88 | 49.83 | 43.53 | Upgrade
|
| Loss (Gain) From Sale of Assets | -107.74 | -107.74 | -11.12 | -12.03 | -0.69 | -0.69 | Upgrade
|
| Asset Writedown & Restructuring Costs | 3.92 | 3.92 | 2.93 | -0.42 | 7.06 | 3.08 | Upgrade
|
| Loss (Gain) From Sale of Investments | -416.45 | -416.45 | 39.18 | -288.71 | -417.58 | -390.47 | Upgrade
|
| Provision & Write-off of Bad Debts | 102.09 | 102.09 | 58.81 | 73.53 | 54.55 | 95.1 | Upgrade
|
| Other Operating Activities | 2,274 | 556.97 | 608.18 | 660.47 | 715.79 | 659.84 | Upgrade
|
| Change in Accounts Receivable | -2,542 | -2,542 | -255.91 | -417.27 | -1,992 | -1,627 | Upgrade
|
| Change in Inventory | -351.71 | -351.71 | -1,314 | -835.03 | -242.22 | -673.65 | Upgrade
|
| Change in Accounts Payable | -1,474 | -1,474 | 602.7 | -66.12 | 4,121 | 3,158 | Upgrade
|
| Operating Cash Flow | 1,447 | -232.46 | 3,442 | 4,104 | 6,999 | 5,673 | Upgrade
|
| Operating Cash Flow Growth | -46.07% | - | -16.11% | -41.37% | 23.36% | 869.52% | Upgrade
|
| Capital Expenditures | -1,238 | -1,240 | -1,128 | -1,628 | -1,384 | -1,255 | Upgrade
|
| Sale of Property, Plant & Equipment | 200.33 | 120.33 | 2.36 | 13.93 | 1.49 | 6.61 | Upgrade
|
| Cash Acquisitions | -387.3 | 2.26 | -1.57 | - | 147.67 | -1.39 | Upgrade
|
| Divestitures | -0.98 | -0.98 | - | - | - | 32.57 | Upgrade
|
| Investment in Securities | -5,778 | -3,380 | -5,053 | -1,885 | -6,233 | 42.79 | Upgrade
|
| Other Investing Activities | 529.73 | 490.7 | 216.09 | 384.46 | 214.82 | 242.77 | Upgrade
|
| Investing Cash Flow | -6,675 | -4,007 | -5,964 | -3,115 | -7,253 | -931.57 | Upgrade
|
| Short-Term Debt Issued | - | 299.98 | - | 299.96 | 599.91 | - | Upgrade
|
| Long-Term Debt Issued | - | 12,685 | 9,954 | 9,604 | 9,696 | 8,826 | Upgrade
|
| Total Debt Issued | 15,808 | 12,985 | 9,954 | 9,904 | 10,296 | 8,826 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -900 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -11,387 | -8,648 | -9,646 | -8,422 | -8,943 | Upgrade
|
| Total Debt Repaid | -12,207 | -11,387 | -8,648 | -10,546 | -8,422 | -8,943 | Upgrade
|
| Net Debt Issued (Repaid) | 3,601 | 1,598 | 1,306 | -642.15 | 1,874 | -116.76 | Upgrade
|
| Common Dividends Paid | -1,654 | -1,648 | -2,251 | -1,585 | -1,491 | -1,266 | Upgrade
|
| Other Financing Activities | 539.73 | 539.04 | -61.59 | 249.35 | -337.16 | -111.17 | Upgrade
|
| Financing Cash Flow | 2,487 | 489.35 | -1,006 | -1,978 | 45.95 | -1,494 | Upgrade
|
| Foreign Exchange Rate Adjustments | -4.35 | 3.85 | 7.14 | 8.08 | -0.5 | 0.28 | Upgrade
|
| Net Cash Flow | -2,745 | -3,747 | -3,521 | -981.16 | -208.67 | 3,248 | Upgrade
|
| Free Cash Flow | 209.1 | -1,472 | 2,314 | 2,475 | 5,615 | 4,419 | Upgrade
|
| Free Cash Flow Growth | -87.31% | - | -6.50% | -55.92% | 27.08% | - | Upgrade
|
| Free Cash Flow Margin | 0.27% | -1.90% | 3.09% | 3.28% | 7.93% | 6.40% | Upgrade
|
| Free Cash Flow Per Share | 0.13 | -0.91 | 1.42 | 1.52 | 3.45 | 2.72 | Upgrade
|
| Cash Income Tax Paid | 2,822 | 2,822 | 2,729 | 3,140 | 2,759 | 2,873 | Upgrade
|
| Levered Free Cash Flow | -10,713 | -2,421 | 838.99 | 1,169 | 3,947 | 1,963 | Upgrade
|
| Unlevered Free Cash Flow | -10,461 | -2,170 | 1,100 | 1,448 | 4,219 | 2,224 | Upgrade
|
| Change in Working Capital | -4,317 | -4,317 | -1,028 | -1,372 | 1,879 | 860.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.